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Abstract
Background: Salvage chemotherapy is the mainstay of treatment for metastatic gastric cancer (mGC). This study
aimed to clarify the effects of palliative gastrectomy (PG) and identify prognostic factors in mGC patients
undergoing PG.
Methods: This was a retrospective review of 333 mGC patients receiving PG or a non-resection procedure (NR)
between 2000 and 2010. Clinicopathological factors affecting the prognosis of these patients were collected
prospectively and analyzed.
Results: One hundred and ninety-three patients underwent PG and 140 NR. The clinicopathological characteristics
were comparable between the two groups except for metastatic pattern. There were no significant differences in
postoperative morbidity and mortality between the two groups. The PG group had a significantly longer median
overall survival compared with the NR group (7.7 months vs. 4.9 months). In the PG group, age ≤58 years,
preoperative albumin level >3 g/dL, ratio of metastatic to examined lymph nodes ≤0.58, and administration of
chemotherapy were independent prognostic factors in multivariate analysis.
Conclusions: Patients undergoing PG had better outcomes than those undergoing NR. Among the patients
undergoing resection, age ≤58 years, a better preoperative nutritional status, less nodal involvement and
postoperative chemotherapy independently affected patient survival.
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Background
Even though the incidence of gastric cancer (GC) has
decreased over the past 3 decades, it was still the third
leading cancer-related cause of death worldwide in 2012
[1]. Surgical resection with adequate lymphadenectomy
provides the best chance of a cure [2, 3]. However, most
patients present with locally advanced or metastatic dis-
ease at the time of diagnosis, with a 5-year survival rate
of around 10% [4, 5]. Patients with inoperable or meta-
static disease usually die within 12 months with or with-
out salvage chemotherapy [6, 7]. However, patients with
tumor-associated symptoms including dysphagia, gastric
outlet obstruction, bleeding or gastric perforation may
need a surgical intervention. Our previous studies
showed that although GC tends to exhibit a more aggres-
sive tumor behavior in young patients than in old patients,
young patients with metastatic disease undergoing
palliative gastrectomy (PG) have better outcomes than old
patients [8]. A systemic review and meta-analysis of retro-
spective non-randomized studies indicated that PG may
be beneficial compared with non-resection treatment for
patients with metastatic GC (mGC); however, questions
regarding which patients are suitable for PG remain un-
answered [9]. Therefore, the aims of the present study
were to detail the clinicopathological parameters that ob-
jectively affect clinicians’ decision-making, elucidate post-
operative morbidity and mortality, and determine the
prognostic factors for selecting appropriate candidates for
PG in a tertiary medical center.
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Methods
Patients and surgical procedures
Between 2000 and 2010, 333 pathologically proven mGC
patients undergoing PG or a non-resection procedure (NR)
in Taiwan were enrolled. In general, gastrectomy was not
performed in the patients who did not have tumor-
associated symptoms or in those with peritoneal metastasis
for which macroscopic curative resection was not expected.
The patients with tumor-related symptoms or solitary dis-
tant visceral organ metastasis such as the ovary or liver for
which complete resection of the metastatic tumor was feas-
ible underwent PG (D1 or D2 lymphadenectomy) or gas-
trectomy (D2 lymphadenectomy) plus metastasectomy.
The NRs included bypass surgery, laparoscopic/laparotomy
biopsy, feeding jejunostomy, hemostasis (suture ligation of
a bleeder), and gastrorrhaphy (repair of a perforation). No
patient received preoperative chemotherapy or stent place-
ment for obstruction symptoms. The tumors were staged
according to the seventh edition of the American Joint
Committee on Cancer Tumor Node Metastasis classifica-
tion [10]. Suitable patients received salvage chemotherapy
with fluoropyrimidine-based or platinum-based regimens.
Clinical data collection
Patient demographics, clinicopathological features, Charlson
comorbidity index score and surgical outcomes were com-
pared between the PG and NR groups. The median follow-
up times in the PG and NR groups were 7.2 months and
4.7 months, respectively. The overall survival of the patients
in the PG group was evaluated and compared with that of
the NR patients operated on during the same time period.
The patients who died during the same hospitalization after
surgery were included in the survival analysis. Survival dur-
ation was calculated from the time of surgery to death or
the last follow-up date (August 31, 2012).
Statistical analysis
Non-binomially distributed data are presented as median
(range). Clinical records were compared using the Student’s
t-test or Pearson’s chi-square test, as appropriate. Patient
GC-specific survival was estimated using the Kaplan-Meier
method, and differences between subgroups were assessed
using the log-rank test. Potentially important factors ob-
tained using univariate analysis (P <0.1) were included in
multivariate analysis, and both analyses were performed
using a Cox proportional hazards model. A P value of less
than 0.05 was considered to be statistically significant. All
statistical analyses were performed using the Statistical
Package for the Social Sciences version 20.0 for Windows
(SPSS Inc., Chicago, IL, USA).
Results
As shown in Table 1, no significant differences were
found between the PG and NR groups in terms of age,
gender, platelet count, hemoglobin, levels of albumin,
alanine aminotransferase, aspartate aminotransferase,
alkaline phosphatase, total bilirubin and creatinine,
Charlson comorbidity index score, tumor-associated
symptoms, and percentage of postoperative salvage
chemotherapy. The PG group had a higher and lower
proportion of hematogenous spread alone and peritoneal
metastasis than the NR group, respectively (P <0.029).
There were no differences in surgical complications and
in-hospital mortality or mortality within 30 days after
surgery between the two groups. The PG group had a
higher percentage of patients who survived for more
than 12 months compared with the NR group. (29.5%
vs. 15.7%; P =0.005).
The patients in the PG group had a significantly longer
median overall survival time compared with those in the
NR group (7.7 months vs. 4.9 months; P <0.0001; Fig. 1).
The overall survival rates in the PG group at 1, 2, and
3 years were 30.2, 8.6, and 4.0%, respectively. The patients
treated with PG and postoperative salvage chemotherapy
had a markedly longer median overall survival time than
those receiving PG or salvage chemotherapy alone, or the
NR group without chemotherapy (P <0.0001; Fig. 2). The
1-, 2-, and 3-year survival rates were 37.0, 11.8, and 6.5%,
respectively, for patients undergoing PG and chemother-
apy, and 2.9, 1.8 and 0% for patients without resection and
chemotherapy. Thirteen and 6 patients underwent ovari-
ectomy and hepatectomy in addition to gastrectomy (D2
lymphadenectomy), respectively. No mortality was noted
in these patients. Among 17 patients with ovarian metas-
tasis, thirteen patients undergoing PG along with resec-
tion of ovary had significantly longer median overall
survival compared with 4 patients not undergoing resec-
tion (15.9 months vs. 5.9 months; P =0.027). The 1-, 3-,
and 5-year survival rates were 61.5, 15.4, and 7.7%,
respectively, in the patients who underwent ovariectomy,
and the 1-, 2-, and 3-year survival rates were 66.7, 33.3,
and 16.7%, respectively, in the patients who underwent
hepatectomy.
Table 2 shows the univariate analysis of various clinico-
pathological factors associated with surgical outcomes in
the PG group. Age, gender, albumin level, tumor-
associated symptoms, nodal involvement, ratio of meta-
static to examined lymph nodes, lymphatic and perineural
invasion as well as the administration of postoperative
chemotherapy significantly affected the prognosis. No sig-
nificant differences in overall survival time were observed
for levels of alkaline phosphatase and total bilirubin, the
type of gastrectomy, tumor location, differentiation,
Lauren’s histological type, depth of tumor invasion, num-
ber of lymph nodes retrieved, vascular invasion and meta-
static pattern. In multivariate analysis, the independent
prognostic predictors were age ≤58 years, a preoperative al-
bumin level >3 g/dL, a ratio of metastatic to examined
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lymph nodes ≤0.58 and administration of salvage chemo-
therapy (Table 3).
Discussion
In the present study, there were no differences in surgi-
cal complications and mortality rates between the PG
and NR groups. The median overall survival time was
longer in the mGC patients undergoing PG compared
with NR. The patients receiving PG and postoperative
salvage chemotherapy had better outcomes than those
with other management. In the PG group, age ≤58 years,
preoperative albumin level >3 g/dL, ratio of metastatic
to examined lymph nodes ≤0.58 and administration of
chemotherapy were independent prognostic factors.
It has been reported that young patients undergoing
curative resection have a longer survival duration than
old patients in multivariate analysis [11]. Our previous
research also indicated that for patients with mGC, the
younger patients (age ≤40 years) had significantly better
outcomes than the older (age between 56 and 75 years)
patients after PG [8]. Dittmr et al. reported that compar-
ing mGC patients receiving PG with those receiving NR,
an age <50 years was a predictor for improved survival
in univariate analysis but not in multivariate analysis






Age (years), median (range) 65 (26–89) 63 (22–91) 0.782
Gender 0.393
Male 126 (65.3) 85 (60.7)
Female 67 (34.7) 55 (39.3)
Platelet (103/uL), median (range) 258.5 (58–680) 281 (73–622) 0.609
Hemoglobin (g/dL), median (range) 10.9 (3.8–20.6) 11.0 (4.0–16.5) 0.881
Albumin (g/dL), median (range) 3.7 (1.7–4.9) 3.7 (1.9–4.9) 0.135
AST (U/L), median (range) 18 (5–223) 19 (4–340) 0.491
ALT (U/L), median (range) 14 (1–156) 14 (2–106) 0.975
ALK-P (U/L), median (range) 67 (20–349) 64 (30–459) 0.998
Total bilirubin, (mg/dL) (range) 0.6 (0.2–1.8) 0.6 (0.2–2.0) 0.252
Creatinine (mg/dL), median (range) 0.9 (0.3–11.2) 1.0 (0.4–3.4) 0.500
Charlson comorbidity index score 0.529
2 89 (46.1) 74 (52.9)
3 71 (36.8) 47 (33.6)
4 21 (10.9) 10 (7.1)
≥ 5 12 (6.2) 9 (6.4)
Tumor-associated symptoms 110 (57.0) 82 (58.6) 0.774
Metastatic pattern 0.029
Hematogenous spread alone 56 (29.0) 26 (18.6)
Peritoneum 137 (71.0) 114 (81.4)
Complications 36 (18.7) 28 (20.0) 0.758
In-hospital mortality 20 (10.4) 13 (9.3) 0.745
Mortality within 1 month 14 (7.3) 6 (4.3) 0.260
Chemotherapy 124 (64.2) 83 (59.3) 0.357
Survival time (months) 0.005
≤ 6 82 (42.5) 81 (57.9)
6 ~ 12 54 (28.0) 37 (26.4)
> 12 57 (29.5) 22 (15.7)
Figures are numbers with percentages in parentheses, unless otherwise stated
Hematogenous spread alone indicates metastases to the distant organ or distant nodes
Tumor-associated symptoms include dysphagia, obstruction, bleeding or perforation
ALT alanine aminotransferase, AST aspartate aminotransferase, ALK-P alkaline phosphatase
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Fig. 1 Overall survival (OS) rates of patients with metastatic gastric cancer in terms of resectability
Fig. 2 Overall survival (OS) rates of patients with metastatic gastric cancer in terms of resection and chemotherapy
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Table 2 Univariate analysis of prognostic factors of metastatic gastric cancer patients undergoing resection
Factors Median survival (months) 95% CI of median 1-year (%) 3-year (%) P value
Age (years) 0.003
≤ 58 (n = 71) 10.85 9.03–12.67 42.3 5.1
> 58 (n = 122) 6.15 5.28–7.02 23.2 3.4
Gender 0.009
Male (n = 126) 7.23 5.42–9.05 23.8 1.3
Female (n = 67) 10.98 6.19–15.77 41.8 8.3
Albumin (g/dL) 0.001
≤ 3 (n = 37) 4.44 3.65–5.23 17.5 0.0
> 3 (n = 129) 8.52 6.54–10.49 36.0 3.8
ALK-P (U/L) 0.185
≤ 60 (n = 57) 10.82 8.63–13.01 42.1 4.4
> 60 (n = 92) 7.10 5.33–8.87 26.1 3.3
Total bilirubin (mg/dL) 0.359
≤ 1.3 (n = 153) 8.25 6.90–9.60 32.2 4.4
> 1.3 (n = 6) 3.58 0.23–2.94 16.7 0.0
Gastrectomy 0.525
total (n = 84) 8.52 5.39–11.64 33.4 3.5
subtotal (n = 89) 6.61 5.05–8.17 27.4 4.3
Location 0.161
upper (n = 44) 10.55 7.39–13.72 41.9 7.7
middle (n = 29) 8.06 4.92–11.19 36.3 0.0
lower (n = 97) 6.61 5.54–7.68 24.1 5.9
diffuse (n = 22) 6.38 0.60–12.16 27.3 0.0
Tumor-associated symptoms 0.008
no (n = 83) 12.63 10.04–15.23 40.4 4.3
yes (n = 110) 8.88 7.21–10.56 22.7 4.1
Differentiation 0.549
yes (n = 44) 8.52 5.99–11.04 34.1 2.3
no (n = 149) 7.10 5.35–8.85 29.0 4.6
Lauren’s classification 0.445
intestinal (n = 57) 8.91 6.44–11.38 31.6 4.0
diffuse (n = 101) 6.94 4.99–8.88 27.2 3.8
mixed (n = 31) 7.23 3.55–10.92 37.2 6.8
T status 0.143
1/2/3 (n = 19) 10.85 8.08–13.62 36.8 15.8
4 (n = 174) 7.17 5.63–8.701 29.4 3.4
N status 0.042
0 (n = 12) 11.67 5.14–18.20 50.0 16.7
1 (n = 12) 13.71 7.24–20.18 66.7 0.0
2 (n = 32) 6.54 3.78–9.30 16.1 3.2
3 (n = 137) 3.94 5.24–8.63 28.4 3.4
LN ratioa 0.003
≤ 0.58 (n = 97) 10.39 8.12–12.66 35.4 5.9
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[12]. Lim et al. found that an age <60 years was associ-
ated with prolonged survival in mGC patients undergo-
ing resection in univariate analysis [13]. Since the
median age of patients in the PG group surviving more
than 12 months was 58 years in the present study (data
not shown), we selected the cutoff value 58 years as one
of prognostic covariates. Our results demonstrate that
an age ≤58 years was as a prognostic factor for mGC pa-
tients undergoing PG in multivariate analysis. We specu-
lated that young patients who had better visceral organ
functional reserve and less concomitant comorbidities
than the old after PG than did in the old might therefore
in part explain favorable outcomes in the young.
Koo et al. developed a prognostic model using 2805
patients with metastatic or recurrent GC undergoing
chemotherapy, and found that Eastern Cooperative
Oncology Group (ECOG) performance status ≥2, no gas-
trectomy, presence of peritoneal, bone, or lung metastases,
high levels of serum alkaline phosphatase (>120 U/L) and
total bilirubin (>1.2 mg/dL), and a low serum albumin level
(<3.3 g/dL) were poor prognostic factors [14]. Lee et al.
also reported an estimated median survival of <3 months
in mGC patients receiving chemotherapy with more than
four unfavorable factors (no gastrectomy, albumin
<3.6 g/dL, alkaline phosphatase >85 U/L, ECOG perform-
ance status ≥2, presence of bone metastasis, ascites) [15].
The present study showed that apart from an age ≤58 years,
a serum albumin level >3 g/dL, ratio of metastatic to ex-
amined lymph nodes ≤0.58, and administration of postop-
erative chemotherapy were independent predictors for
survival in the mGC patients undergoing PG suggesting
that patients with above-mentioned favorable factors may
benefit greatly from PG.
It has been reported that a subgroup of GC patients
with ovarian metastasis (Krukenberg tumors) may bene-
fit from resection of the ovary when the gross tumors
are thoroughly removed [16, 17]. Peng et al. reported
that ovarian metastasectomy significantly prolonged the
median overall survival in select GC patients without asci-
tes (21 months vs. 13 months, P = 0.008) or patients under-
going gastrectomy (19 months vs. 9 months, P = 0.048)
[16]. Ayhan et al. also found that survival was significantly
superior in GC patients with ovarian metastasis who under-
went cytoreduction.17 In the present study, thirteen patients
with Krukenberg tumors alone underwent gastrectomy
with D2 lymphadenectomy and ovariectomy, and the
Table 2 Univariate analysis of prognostic factors of metastatic gastric cancer patients undergoing resection (Continued)
> 0.58 (n = 96) 5.56 4.24–6.88 28.9 2.2
No. of lymph node retrieved 0.881
< =15 (n = 47) 5.03 2.47–7.59 27.7 6.4
> 15 (n = 146) 8.32 6.94–9.70 30.9 3.1
Resection margins 0.675
Positive (n = 52) 6.61 3.40–9.82 32.6 0.0
Negative (n = 141) 8.06 6.53–9.58 29.3 4.8
Vascular invasion 0.611
Positive (n = 70) 8.52 6.42–10.09 28.2 4.1
Negative (n = 118) 7.17 5.28–9.05 27.8 3.1
Lymphatic invasion 0.066
Positive (n = 171) 7.17 5.55–8.77 28.2 4.1
Negative (n = 19) 11.67 7.56–15.79 47.4 5.3
Perineural invasion 0.047
Positive (n = 147) 7.17 5.53–8.80 27.0 3.2
Negative (n = 42) 9.27 4.78–13.77 41.8 7.4
Metastatic pattern 0.891
Hematogenous spread alone (n = 56) 5.59 4.67–6.51 28.6 6.0
Peritoneum (n = 137) 8.48 7.00–9.96 30.8 3.2
Chemotherapy <0.0001
No (n = 69) 4.54 2.72–6.36 17.7 0.0
Yes (n = 124) 9.73 7.77–11.69 37.0 6.5
Hematogenous spread alone indicates metastases to the distant organ or distant nodes
Tumor-associated symptoms include dysphagia, obstruction, bleeding or perforation
ALK-P alkaline phosphatase, CI confidence interval
aratio of metastatic to examined lymph nodes
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median survival time was 15.9 months (range 4.4 months
to 64.9 months). Our results supported that PG along with
resection of ovarian metastasis can improve patient’s overall
survival compared with no ovariectomy (median, 15.9 vs.
5.9 months).
The management of GC patients with liver metastasis
remains controversial. Although evidence supporting the
role of hepatectomy in the treatment of these patients is
weak, a survival advantage has been reported in a select
group [18]. However, only 10–20% of GC patients with
liver metastasis are candidates for hepatic resection [19].
The beneficial effects of hepatic resection or radiofre-
quency ablation for GC patients with synchronous liver
metastasis have also been reported [20, 21], with 1-, 2-,
and 3-year overall survival rates after resection of 70, 11,
and 5%, respectively [20]. Furthermore, Cheon et al. also
suggested that hepatic resection should be considered as
an option for GC patients with liver metastasis [22]. The
number of liver metastases has been shown to be an in-
dependent prognostic factor for patients after hepatec-
tomy [21], and those with a solitary liver metastasis have
been reported to have a better survival rate than those
with multiple liver metastases [18, 21]. Recently, Tiberio
et al. reported 1-, 3-, and 5-year survival rates of 50.4,
14.0, and 9.3%, respectively, for 53 GC patients with syn-
chronous liver metastases who underwent gastrectomy
and R0 hepatectomy, and 6.8, 2.3 and 0% for 44 patients
after palliative surgery without resection [23]. Similar to
these results, six patients in the current study with a
solitary synchronous liver metastasis who underwent
gastrectomy with D2 lymphadenectomy and R0 hepatec-
tomy had a median survival of 20.8 months (range
6.6 months to 38.6 months) and 1-, 2-, and 3-year over-
all survival rates of 66.7, 33.3, and 16.7%, respectively.
For patients with metastatic disease, salvage chemo-
therapy is the mainstay of treatment, with reported me-
dian survival times ranging from 5.7 to 11.2 months,
regardless of the chemotherapy regimen [24–26]. How-
ever, some patients with tumor-related complications,
such as gastrointestinal obstruction, bleeding, and gas-
tric perforation may necessitate surgery [27]. Our find-
ings indicated that PG followed by postoperative salvage
chemotherapy significantly prolonged the overall sur-
vival of the mGC patients compared to those without
gastrectomy and chemotherapy. The median overall sur-
vival time of the patients with PG and chemotherapy
was 9.7 months compared to 4.5 months for those who
received PG alone. Of note, the patients in the NR group
did not receive chemotherapy; the median overall sur-
vival time was only 2.9 months. Therefore, we suggest
that in highly select patients with metastatic disease, PG
and chemotherapy should be considered not only to re-
lieve tumor-associated symptoms and improve quality of
life but also to enhance survival benefit. This is also
supported by other studies [9, 23, 28–30]. The possible
reason why PG improves patient outcomes might be asso-
ciated with reducing tumor burden and rendering the pa-
tients more responsive to salvage chemotherapy. In
addition, it has been shown that cytoreductive surgery
diminishes a hypercatabolic state and confers immuno-
logical benefits through decreasing the release of tumor-
derived immunosuppressive cytokines [31]. However,
further research is needed to prove this hypothesis because
selection bias/confounder exists in the current study.
The limitations of the present study are its retrospect-
ive design and that patients were enrolled in a single in-
stitution. The PG group had a significantly higher
proportion of hematogenous spread alone and lower
proportion of peritoneal metastasis than the NR group
(P =0.029). Of note, compared with the NR group, the
PG group did not increase surgical mortality and had
longer survival. However, Tokunaga et al. reported that
patients with peritoneal metastasis did not benefit from
PG [32, 33]. To confirm whether PG can provide sur-
vival benefits in patients with mGC, two large random-
ized controlled clinical studies are performed [34, 35].
Fujitani K et al. indicated that gastrectomy (restricted to
Table 3 Multivariate analysis of prognostic factors in metastatic
gastric cancer patients undergoing resection
Factors Hazard ratio (95% CI) P value
Age (years)
> 58/≤58 1.47 (1.01–2.13) 0.045
Gender
Male/female 1.14 (0.80–1.63) 0.465
Albumin (g/dL)
≤ 3 />3 1.93 (1.24–3.00) 0.003
Tumor-associated symptoms
Yes/no 1.04 (0.73–1.47) 0.837
N status
N1/N0 0.83 (0.33–2.10) 0.695
N2/N0 1.30 (0.56–3.01) 0.542
N3/N0 1.16 (0.49–2.72) 0.740
LN ratioa
> 0.58/≤0.58 1.47 (1.01–2.15) 0.047
Lymphatic invasion
Yes/no 1.20 (0.62–2.32) 0.588
Perineural invasion
Yes/no 1.08 (0.70–1.65) 0.728
Chemotherapy
No/yes 1.68 (1.19–2.38) 0.004
CI confidence interval
Tumor-associated symptoms include dysphagia, obstruction, bleeding
or perforation
aratio of metastatic to examined lymph nodes
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D1 lymphadenectomy without any resection of meta-
static lesions, R2 resection) followed by salvage chemo-
therapy did not provide survival benefit compared with
chemotherapy alone in mGC with a single non-curable
factor (confined to the liver, peritoneum, or para-aortic
lymph nodes) [34]. Different from their studies, we per-
formed gastrectomy with D2 lymphadenectomy and
metastasectomy to achieve grossly R0 resection in some
patients with synchronous solitary metastasis. In addition,
select patients with tumor-associated symptoms including
dysphagia, gastric outlet obstruction, bleeding or perfor-
ation were treated by PG to relieve symptoms. Our results
also indicated that mGC patients receiving PG and salvage
chemotherapy had better survival than salvage chemother-
apy alone. Therefore, based on our current results, we
suggest that PG should be considered in patients with fa-
vorable factors when only solitary metastasis was detected.
Conclusions
Among the mGC patients undergoing palliative resection,
age ≤58 years, a better pre-operative nutritional status, less
nodal involvement and administration of chemotherapy
were independent prognostic factors in multivariate ana-
lysis. The patients treated with a combination of PG and
salvage chemotherapy had a longer survival time than
those who received other management strategies. We
recommend that mGC patients with these favorable prog-
nostic factors and favorable general performance status
should undergo PG with R0 metastasectomy if achievable
followed by salvage chemotherapy.
Abbreviations
ECOG: Eastern Cooperative Oncology Group; mGC: Metastatic gastric cancer;
NR: Non-resection procedure; PG: Palliative gastrectomy
Acknowledgements
The authors thank Shu-Fang Huang for updating the database, performing
data analysis and her assistance in the preparation of the figures.
Funding
This work was partly supported by the Chang Gung Medical Research Program,
Taiwan (CMRPG3C0601, CMRPG3C0602 and CORPG3E0152). The funding source
was not involved in study design, collection, analysis, and interpretation of the
data, and writing of the manuscript.
Availability of data and materials
Ethical restrictions and local data protection regulations do not allow publication
of raw data. All relevant data for the conclusions are presented in the manuscript.
Authors’ contributions
HJT: study design and analysis, management of patients, drafting and revising
manuscript; LJA: data collection, study analysis. CHC: pathological review of
surgical specimen; CTD: pathological review of surgical specimen; CTH:
management of patients; KCJ: management of patients; LCJ: management of
patients; CWC: management of patients; YTS: management of patients; JYY:
management of patients. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
This study does not contain any individual person data.
Ethics approval and consent to participate
This study was reviewed and approved by the Institutional Review Board of
Chang Gung Memorial Hospital (No.: 100-4279B). All data were stored in the
hospital database and used for research.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Surgery, Chang Gung Memorial Hospital at Linkou, Chang
Gung University College of Medicine, #5, Fushing Street, Kweishan District,
Taoyuan City 333, Taiwan. 2Department of Pathology, Chang Gung Memorial
Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan City
333, Taiwan. 3Department of Gastroenterology, Chang Gung Memorial
Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan City
333, Taiwan. 4Department of Hematology-Oncology, Chang Gung Memorial
Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan City
333, Taiwan.
Received: 20 May 2016 Accepted: 7 March 2017
References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al.
Cancer incidence and mortality worldwide: sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
2. Hsu JT, Lin CJ, Sung CM, Yeh HC, Chen TH, Chen TC, et al. Prognostic
significance of the number of examined lymph nodes in node-negative
gastric adenocarcinoma. Eur J Surg Oncol. 2013;39:1287–93.
3. Cheng CT, Tsai CY, Hsu JT, Vinayak R, Liu KH, Yeh CN, et al. Aggressive
surgical approach for patients with T4 gastric carcinoma: promise or myth?
Ann Surg Oncol. 2011;18:1606–14.
4. Wang F, Chang YC, Chen TH, Hsu JT, Kuo CJ, Lin CJ, et al. Prognostic
significance of splenectomy for gastric cancer patients undergoing total
gastrectomy: a retrospective cohort study. Int J Surg. 2014;12:557–65.
5. Tegels JJ, De Maat MF, Hulsewé KW, Hoofwijk AG, Stoot JH. Improving the
outcomes in gastric cancer surgery. World J Gastroenterol. 2014;20:13692–704.
6. Hsu JT, Chen TC, Tseng JH, Chiu CT, Liu KH, Yeh CN, et al. Impact of HER-2
overexpression/amplification on the prognosis of gastric cancer patients
undergoing resection: a single-center study of 1,036 patients. Oncologist.
2011;16:1706–13.
7. Takeno A, Takiguchi S, Fujita J, Tamura S, Imamura H, Fujitani K, et al.
Clinical outcome and indications for palliative gastrojejunostomy in
unresectable advanced gastric cancer: multi-institutional retrospective
analysis. Ann Surg Oncol. 2013;20:3527–33.
8. Hsieh FJ, Wang YC, Hsu JT, Liu KH, Yeh CN, Yeh TS, et al. Clinicopathological
features and prognostic factors of gastric cancer patients aged 40 years or
younger. J Surg Oncol. 2012;105:304–9.
9. Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O.
Gastrectomy for stage IV gastric cancer. a systematic review and meta-
analysis. Anticancer Res. 2014;34:2079–85.
10. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, American
Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th ed. New
York: Springer; 2009.
11. Park JC, Lee YC, Kim JH, Kim YJ, Lee SK, Hyung WJ, et al. Clinicopathological
aspects and prognostic value with respect to age: an analysis of 3,362
consecutive gastric cancer patients. J Surg Oncol. 2009;99:395–401.
12. Dittmar Y, Rauchfuss F, Goetz M, Jandt K, Scheuerlein H, Heise M, et al.
Non-curative gastric resection for patients with stage 4 gastric cancer–a
single center experience and current review of literature. Langenbecks Arch
Surg. 2012;397:745–53.
13. Lim S, Muhs BE, Marcus SG, Newman E, Berman RS, Hiotis SP. Results
following resection for stage IV gastric cancer; are better outcomes
observed in selected patient subgroups? J Surg Oncol. 2007;95:118–22.
14. Koo DH, Ryoo BY, Kim HJ, Ryu MH, Lee SS, Moon JH. A prognostic model in
patients who receive chemotherapy for metastatic or recurrent gastric cancer:
validation and comparison with previous models. Cancer Chemother
Pharmacol. 2011;68:913–21.
Hsu et al. BMC Palliative Care  (2017) 16:19 Page 8 of 9
15. Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, et al. Prognostic model to
predict survival following first-line chemotherapy in patients with metastatic
gastric adenocarcinoma. Ann Oncol. 2007;18:886–91.
16. Peng W, Hua RX, Jiang R, Ren C, Jia YN, Li J, et al. Surgical treatment for
patients with Krukenberg tumor of stomach origin: clinical outcome and
prognostic factors analysis. PLoS One. 2013;8:e68227.
17. Ayhan A, Guvenal T, Salman MC, Ozyuncu O, Sakinci M, Basaran M. The role
of cytoreductive surgery in nongenital cancers metastatic to the ovaries.
Gynecol Oncol. 2005;98:235–41.
18. Grimes N, Devlin J, Dunne DF, Poston G, Fenwick S, Malik H. The role of
hepatectomy in the management of metastatic gastric adenocarcinoma: a
systematic review. Surg Oncol. 2014;23:177–85.
19. Okano K, Maeba T, Ishimura K, Karasawa Y, Goda F, Wakabayashi H, et al.
Hepatic resection for metastatic tumors from gastric cancer. Ann Surg.
2002;235:86–91.
20. Chen J, Tang Z, Dong X, Gao S, Fang H, Wu D, et al. Radiofrequency ablation
for liver metastasis from gastric cancer. Eur J Surg Oncol. 2013;39:701–6.
21. Qiu JL, Deng MG, Li W, Zou RH, Li BK, Zheng Y, et al. Hepatic resection for
synchronous hepatic metastasis from gastric cancer. Eur J Surg Oncol.
2013;39:694–700.
22. Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, et al. Survival benefit
of combined curative resection of the stomach (D2 resection) and liver in
gastric cancer patients with liver metastases. Ann Oncol. 2008;19:1146–53.
23. Tiberio GA, Baiocchi GL, Morgagni P, Marrelli D, Marchet A, Cipollari C, et al.
Gastric cancer and synchronous hepatic metastases: is it possible to
recognize candidates to R0 resection? Ann Surg Oncol. 2015;22:589–96.
24. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al.
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl
J Med. 2008;358:36–46.
25. Wagner AD, Grothe W, Haerting J, Haerting J, Kleber G, Grothey A, et al.
Chemotherapy in advanced gastric cancer: a systematic review and meta-
analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.
26. Kanat O, O’Neil BH. Metastatic gastric cancer treatment: a little slow but
worthy progress. Med Oncol. 2013;30:464.
27. Cunningham SC, Schulick RD. Palliative management of gastric cancer. Surg
Oncol. 2007;16:267–75.
28. Sun J, Song Y, Wang Z, Chen X, Chen X, Gao P, Xu Y, et al. Clinical
significance of palliative gastrectomy on the survival of patients with
incurable advanced gastric cancer: a systemic review and meta-analysis.
BMC Cancer. 2013;13:577.
29. Sougoultzis S, Syrios J, Xynos ID, Bovaretos N, Kosmas C, Sarantonis J, et al.
Palliative gastrectomy and other factors affecting overall survival in stage IV
gastric adenocarcinoma patients receiving chemotherapy: a retrospective
analysis. Eur J Surg Oncol. 2011;37:312–8.
30. Chen S, Li YF, Feng XY, Zhou ZW, Yuan XH, Chen YB. Significance of
palliative gastrectomy for late-stage gastric cancer patients. J Surg Oncol.
2012;106:862–71.
31. Pollock RE, Roth JA. Cancer-induced immunosuppression: implications for
therapy? Semin Surg Oncol. 1989;5:414–9.
32. Tokunaga M, Terashima M, Tanizawa Y, Bando E, Kawamura T, Yasui H, et al.
Survival benefit of palliative gastrectomy in gastric cancer patients with
peritoneal metastasis. World J Surg. 2012;36:2637–43.
33. Kim KW, Chow O, Parikh K, Blank S, Jibara G, Kadri H, et al. Peritoneal
carcinomatosis in patients with gastric cancer, and the role for surgical
resection, cytoreductive surgery, and hyperthermic intraperitoneal
chemotherapy. Am J Surg. 2014;207:78–83.
34. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al.
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced
gastric cancer with a single non-curable factor (REGATTA): a phase 3,
randomised controlled trial. Lancet Oncol. 2016;17:309–18.
35. Kerkar SP, Kemp CD, Duffy A, Kammula US, Schrump DS, Kwong KF, et al.
The GYMSSA trial: a prospective randomized trial comparing gastrectomy,
metastasectomy plus systemic therapy versus systemic therapy alone. Trials.
2009;10:121.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Hsu et al. BMC Palliative Care  (2017) 16:19 Page 9 of 9
